Literature DB >> 3497347

Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells.

I R Garrett, B G Durie, G E Nedwin, A Gillespie, T Bringman, M Sabatini, D R Bertolini, G R Mundy.   

Abstract

Myeloma cells destroy bone by producing an osteoclast-stimulating factor that has chemical and biological characteristics similar to the bone-resorbing activity present in the supernatants of activated leukocyte cultures. Recently, a number of bone-resorbing leukocyte cytokines have been identified, including interleukin-1, lymphotoxin, and tumor necrosis factor. We have examined the products of human myeloma cells for the presence of these bone-resorbing cytokines. In a tumor cell line derived from a patient who had myeloma with osteolytic bone lesions and hypercalcemia, we found that the myeloma cells induced bone-resorbing activity and cytotoxic activity in vitro. Most of the bone-resorbing activity and all cytotoxic activity were suppressed by neutralizing antibodies to lymphotoxin. The myeloma cells expressed both lymphotoxin and tumor necrosis factor mRNA, but no tumor necrosis factor could be detected in the cell-culture medium. Interleukin-1 mRNA was not detected in the myeloma cells, and biologic activity of interleukin-1 was not measurable in the medium harvested from the cultured cells. The bone-resorbing activity induced by recombinant tumor necrosis factor and recombinant interleukin-1 was not affected by treatment with the lymphotoxin antibodies. When lymphotoxin was infused subcutaneously into normal mice (10 micrograms per day for three days), their plasma calcium levels increased. We also evaluated four established cell lines derived from three other patients with myeloma, and found a similar pattern of lymphotoxin expression in each. It appears that production of the bone-resorbing cytokine lymphotoxin is related to osteoclastic bone destruction and hypercalcemia in patients with myeloma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497347     DOI: 10.1056/NEJM198708273170902

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  54 in total

Review 1.  Endocrine paraneoplastic syndromes with special reference to the elderly.

Authors:  L Bollanti; G Riondino; F Strollo
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

2.  Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.

Authors:  D M Nachbaur; M Herold; A Maneschg; H Huber
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

3.  Osteosclerotic myeloma variants.

Authors:  F M Hall; S M Gore
Journal:  Skeletal Radiol       Date:  1988       Impact factor: 2.199

4.  Treating bony metastases.

Authors:  D Dodwell; A Howell
Journal:  BMJ       Date:  1991-08-24

5.  Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.

Authors:  K Selmaj; C S Raine; B Cannella; C F Brosnan
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

6.  Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha.

Authors:  G Buchan; K Barrett; M Turner; D Chantry; R N Maini; M Feldmann
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

7.  Production of tumor necrosis factors by human T cell lines infected with HTLV-1 may cause their high susceptibility to human immunodeficiency virus infection.

Authors:  N Kobayashi; Y Hamamoto; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

8.  Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization.

Authors:  S Beissert; M Bergholz; I Waase; G Lepsien; A Schauer; K Pfizenmaier; M Krönke
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

Review 9.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

10.  Normal and osteoporotic human osteoblast behaviour after 1,25-dihydroxy-vitamin D(3) stimulation.

Authors:  N Maruotti; A Corrado; M Grano; S Colucci; F P Cantatore
Journal:  Rheumatol Int       Date:  2008-11-07       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.